459 related articles for article (PubMed ID: 34100023)
1. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.
Caniels TG; Bontjer I; van der Straten K; Poniman M; Burger JA; Appelman B; Lavell AHA; Oomen M; Godeke GJ; Valle C; Mögling R; van Willigen HDG; Wynberg E; Schinkel M; van Vught LA; Guerra D; Snitselaar JL; Chaturbhuj DN; Martin IC; ; Moore JP; de Jong MD; Reusken C; Sikkens JJ; Bomers MK; de Bree GJ; van Gils MJ; Eggink D; Sanders RW
medRxiv; 2021 Jun; ():. PubMed ID: 34100023
[TBL] [Abstract][Full Text] [Related]
2. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.
Caniels TG; Bontjer I; van der Straten K; Poniman M; Burger JA; Appelman B; Lavell AHA; Oomen M; Godeke GJ; Valle C; Mögling R; van Willigen HDG; Wynberg E; Schinkel M; van Vught LA; Guerra D; Snitselaar JL; Chaturbhuj DN; Cuella Martin I; ; Moore JP; de Jong MD; Reusken C; Sikkens JJ; Bomers MK; de Bree GJ; van Gils MJ; Eggink D; Sanders RW
Sci Adv; 2021 Sep; 7(36):eabj5365. PubMed ID: 34516917
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
4. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
5. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
6. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination.
Chen X; Chen Z; Azman AS; Sun R; Lu W; Zheng N; Zhou J; Wu Q; Deng X; Zhao Z; Chen X; Ge S; Yang J; Leung DT; Yu H
medRxiv; 2021 May; ():. PubMed ID: 33972950
[TBL] [Abstract][Full Text] [Related]
8. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
Front Immunol; 2021; 12():743422. PubMed ID: 34659239
[TBL] [Abstract][Full Text] [Related]
9. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
10. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
[TBL] [Abstract][Full Text] [Related]
12. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants.
Anichini G; Terrosi C; Gori Savellini G; Gandolfo C; Franchi F; Cusi MG
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34069852
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
16. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
Edara VV; Floyd K; Lai L; Gardner M; Hudson W; Piantadosi A; Waggoner JJ; Babiker A; Ahmed R; Xie X; Lokugamage K; Menachery V; Shi PY; Suthar MS
medRxiv; 2021 Feb; ():. PubMed ID: 33564782
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
19. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
[TBL] [Abstract][Full Text] [Related]
20. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
Andrade VM; Christensen-Quick A; Agnes J; Tur J; Reed C; Kalia R; Marrero I; Elwood D; Schultheis K; Purwar M; Reuschel E; McMullan T; Pezzoli P; Kraynyak K; Sylvester A; Mammen MP; Tebas P; Joseph Kim J; Weiner DB; Smith TRF; Ramos SJ; Humeau LM; Boyer JD; Broderick KE
NPJ Vaccines; 2021 Oct; 6(1):121. PubMed ID: 34650089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
